Clefamide

Clefamide

SCHEMBL672628

O=C(C(Cl)Cl)N(CCO)Cc1ccc(Oc2ccc([N+](=O)[O-])cc2)cc1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.46
ALDH1A1 P00352 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
GAA P10253 1/20 0.44
MC4R P32245 1/20 0.43
CRHBP P24387 1/20 0.43
CRHR2 Q13324 1/20 0.43
KCNH2 Q12809 4/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
NPC1 O15118 1/20 0.42
MAPT P10636 1/20 0.42
MAPK1 P28482 1/20 0.42
RAB9A P51151 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
MYOC Q99972 1/20 0.42
MMP13 P45452 1/20 0.41
TSHR P16473 1/20 0.41
SRD5A2 P31213 1/20 0.41
NR3C1 P04150 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11782643 0.94 LMNA (0.49) LMNAALDH1A1SMN1; SMN2MC4RCRHBP
SCHEMBL11778961 0.91 LMNA (0.51) LMNAALDH1A1SMN1; SMN2CRHBPCRHR2
SCHEMBL11780000 0.91 MC4R (0.53) LMNAALDH1A1SMN1; SMN2MC4RCRHBP
SCHEMBL11780196 0.91 MC4R (0.53) LMNAALDH1A1SMN1; SMN2MC4RCRHBP
Etofamide SCHEMBL1163863 0.85 KCNH2 (0.46) LMNAALDH1A1SMN1; SMN2MC4RCRHBP
SCHEMBL11779835 0.85 ALDH1A1 (0.51) LMNAALDH1A1SMN1; SMN2MC4RCRHBP
SCHEMBL11780584 0.84 LMNA (0.46) LMNAALDH1A1SMN1; SMN2MC4RCRHBP
SCHEMBL11780552 0.84 LMNA (0.45) LMNAALDH1A1SMN1; SMN2MC4RCRHBP
SCHEMBL11779123 0.83 LMNA (0.44) LMNAALDH1A1SMN1; SMN2MC4RCRHBP
SCHEMBL11778824 0.83 MEN1 (0.44) LMNAALDH1A1SMN1; SMN2CRHBPCRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 374 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119409858-A Protonated product of pyridine derivative and compound, preparation method and application thereof 天津师范大学 2025-02-11 CN claimed
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS NEOCULI PTY LTD (AU) 2017-10-12 US claimed
US-9016221-B2 Surface topographies for non-toxic bioadhesion control UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-04-28 US claimed
US-8993117-B2 Devices with multiple surface functionality THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2015-03-31 US claimed
US-20120121661-A1 DEVICES WITH MULTIPLE SURFACE FUNCTIONALITY THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2012-05-17 US claimed
US-20100226943-A1 SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL UNIVERSITY OF FLORIDA (US) 2010-09-09 US claimed
EP-1954244-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY Scidose, Llc (US) 2008-08-13 EP claimed
WO-2007061529-A1 LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY SCIDOSE LLC. (US) 2007-05-31 WO claimed
US-20070116729-A1 Lyophilization process and products obtained thereby SCIDOSE LLC 2007-05-24 US claimed
US-20050142069-A1 Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer NOVADEL PHARMA, INC. 2005-06-30 US claimed
EP-1545458-A2 BUCCAL, POLAR OR NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING AN INFECTIOUS DISEASE OR CANCER Novadel Pharma Inc. (US) 2005-06-29 EP claimed
WO-2004019912-A2 BUCCAL, POLAR OR NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING AN INFECTIOUS DISEASE OR CANCER NOVADEL PHARMA INC. (US) 2004-03-11 WO claimed
US-20030082107-A1 Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer NOVADEL PHARMA INC. 2003-05-01 US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-4092139-B1 METHOD FOR DISCRIMINATING BETWEEN LIVE AND DEAD MICROBES IN A SAMPLE PATHOQUEST (FR) 2026-02-18 EP disclosed
US-20250312349-A1 COMPOSITION AND METHODS OF TREATING INTRACELLULAR PATHOGEN INFECTION UNIV HOSPITALS CLEVELAND MEDICAL CENTER (US) 2025-10-09 US disclosed
WO-1994004352-A1 PARTICLE BINDERS WEYERHAEUSER COMPANY (US) 1994-03-03 WO disclosed
WO-1994004351-A1 PARTICLE BINDING TO FIBERS WEYERHAEUSER COMPANY (US) 1994-03-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170291886-A1 METHODS FOR TREATING PROTOZOAN INFECTIONS DPM1, ABCB11, PIGS LMNA 2337/4885ALDH1A1 840/4885SMN1; SMN2 3002/4885
US-20120121661-A1 DEVICES WITH MULTIPLE SURFACE FUNCTIONALITY PHOSPHO1, CD44, SELP LMNA 4659/4885ALDH1A1 2513/4885SMN1; SMN2 3938/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.